WebMay 28, 2024 · PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced … WebOct 13, 2024 · As a result of the planned withdrawal, BridgeBio will shutter its ongoing Phase III PROOF-301 clinical trial of infigratinib in first-line cholangiocarcinoma (CAA). LianBio, …
PROOF 301: A multicenter, open-label, randomized, phase 3 trial of …
WebMay 26, 2024 · The standard first-line systemic therapy for advanced CCA is a combination of cisplatin + gemcitabine, which was shown by the ABC-02 trial demonstrating a superior median progression-free survival (PFS) (8.0 vs. 5.0 months), disease control rate (DCR) (81.4% vs. 71.8%), and overall survival (11.7 vs. 8.1 months) when compared to … WebJun 30, 2024 · PROOF 301. 1:45 . PROOF 301: infigratinib in advanced CCA. Milind Javle • 30 Jun 2024. VJOncology is intended for Healthcare Professionals only ... Trials; … scottish themed funeral flowers
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter …
WebJun 25, 2024 · In this article we describe the design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, randomized trial of infigratinib in comparison to … WebDec 21, 2024 · The MAGNITUDE phase III clinical trial is testing whether treating metastatic castrate-resistant prostate cancer with the PARP inhibitor drug niraparib (Zejula) in combination with abiraterone (Zytiga) delays cancer growth and helps patients live longer. [3:33] The PROOF 302 phase III clinical trial is studying whether using the FGFR inhibitor ... WebMar 23, 2024 · Milestone will host a conference call and webcast to discuss the results of the NODE-301 trial today, March 23, 2024 at 5:00 p.m. ET. To access the live call by phone, dial (800) 529-3311 (domestic) or (470) 495-9164 (international); the conference ID is 6152207. ... and plans to commence a Phase 2 proof-of-concept trial in atrial fibrillation ... scottish theatre producers